Similarly, recent studies have revealed that CCL2 could activate the PI3K/AKT pathway and resist tumor cell apoptosis and autophagy, thereby leading to resistance to major anticancer agents, such as taxanes [33,34], platinum drugs [27], tamoxifen [38], and temozolomide [37] (Figure 2). Here, CCL2 is linked to neoplasm.